Related Experiment Video
Updated: Sep 14, 2025
Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Synergistic drug combination screening using a nanodroplet processing platform to enhance neuroblastoma treatment in
Yen-Tzu Liao1, Zhi-Kai Yu1, Yi-Xun Huang1
1Department of Life Science National Taiwan University Taipei City Taiwan.
Abstract:
Neuroblastoma is a highly aggressive pediatric cancer with a poor prognosis, particularly in high-risk (HR) cases characterized by MYCN amplification. The severe side effects associated with high-dose chemotherapy further complicate treatment. Despite significant advancements in drug screening, traditional platforms remain limited due to their requirement for large cell quantities and their low translational success from bench to clinic. These limitations hinder the application of personalized medicine screening for patients with neuroblastoma. To address these challenges, we developed a Bioinspired Nanodroplet Processing (BioNDP) platform. This innovative platform allows for the simultaneous screening of multiple drug combinations while reducing the required number of cells to just 100 and minimizing assay volumes to 200 nL per well. Using BioNDP, we screened chemotherapeutic combinations of cyclophosphamide, doxorubicin, and vincristine in both the SK-N-DZ neuroblastoma cell line and primary neuroblastoma cells derived from TH-MYCN transgenic mice. Our findings revealed a specific drug combination that exhibited significant synergistic cytotoxicity in neuroblastoma cells. This combination completely eradicated tumors and significantly improved survival rates in TH-MYCN mice, without notable side effects. This study highlights the potential of the BioNDP platform in bridging in vitro and in vivo results, offering a promising strategy for personalized medicine in the treatment of HR neuroblastoma, with reduced toxicity and enhanced therapeutic efficacy.
Insights
A novel nanodroplet platform enables personalized drug screening for high-risk neuroblastoma, identifying a synergistic combination that eradicates tumors and improves survival in mice with minimal side effects.
Area of Science:
- Oncology
- Biotechnology
- Pediatric Medicine
Background:
- High-risk neuroblastoma (HRNB) presents a poor prognosis, often necessitating aggressive chemotherapy with severe side effects.
- Current drug screening platforms for neuroblastoma are limited by high cell requirements and poor translation to clinical success.
- Personalized medicine approaches are crucial for improving treatment efficacy and reducing toxicity in HRNB.
Purpose of the Study:
- To develop and validate a Bioinspired Nanodroplet Processing (BioNDP) platform for efficient drug screening in neuroblastoma.
- To identify synergistic chemotherapeutic combinations for HRNB treatment using the BioNDP platform.
- To evaluate the efficacy and safety of identified drug combinations in preclinical models.
Main Methods:
- Development of the Bioinspired Nanodroplet Processing (BioNDP) platform for low-cell-input, high-throughput screening.
- Screening of chemotherapeutic combinations (cyclophosphamide, doxorubicin, vincristine) on neuroblastoma cell lines and primary cells.
- In vivo efficacy and toxicity assessment of promising drug combinations in TH-MYCN transgenic mouse models.
Main Results:
- The BioNDP platform successfully screened multiple drug combinations using only 100 cells and 200 nL assay volumes.
- A specific synergistic drug combination demonstrated significant cytotoxicity against neuroblastoma cells.
- This combination led to complete tumor eradication and significantly improved survival rates in TH-MYCN mice, with no observed adverse effects.
Conclusions:
- The BioNDP platform offers a powerful tool for personalized medicine in HRNB, bridging in vitro and in vivo findings.
- The identified synergistic drug combination shows potential for enhanced therapeutic efficacy and reduced toxicity in neuroblastoma treatment.
- This approach paves the way for more effective and tailored treatment strategies for pediatric cancer patients.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024